Online inquiry

IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14589MR)

This product GTTS-WQ14589MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14589MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7246MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ4707MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ11012MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ9124MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ893MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ13933MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ717MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ6939MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ENIA11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW